{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["cell cycle", "molecular docking", "quinazoline", "sulfonamide"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35164248", "DateCompleted": {"Year": "2022", "Month": "02", "Day": "18"}, "DateRevised": {"Year": "2022", "Month": "02", "Day": "19"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "02", "Day": "01"}], "Language": ["eng"], "ELocationID": ["981", "10.3390/molecules27030981"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "27", "Issue": "3", "PubDate": {"Year": "2022", "Month": "Feb", "Day": "01"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "The Antiproliferative and Apoptotic Effects of a Novel Quinazoline Carrying Substituted-Sulfonamides: In Vitro and Molecular Docking Study.", "Abstract": {"AbstractText": ["In order to investigate for a new effective and safe anticancer drug, we synthesized a novel series of quinazoline containing biologically active substituted-sulfonamide moiety at 3- position <b>4a</b>-<b>n</b>. The structure of the newly prepared compounds was proved by microanalysis, IR, <sup>1</sup>H-NMR, <sup>13</sup>C-NMR and mass spectral data. All the synthesized compounds were evaluated for their in vitro cytotoxic activity in numerous cancer cell lines including A549, HepG-2, LoVo and MCF-7 and normal HUVEC cell line. The two most active compounds <b>4d</b> and <b>4f</b> were then tested for their apoptosis induction using DNA content and Annexin V-FITC/PI staining. Moreover, apoptosis initiation was also confirmed using RT-PCR and Western blot. To further understand the binding preferences of quinazoline sulfonamides, docking simulations were used. Among the fourteen new synthesized compounds, we found that compounds <b>4d</b> and <b>4f</b> exerted the strongest cytotoxicity against MCF-7 cells with an IC<sub>50</sub> value of 2.5 and 5 \u03bcM, respectively. Flow cytometry data revealed the ability of compounds <b>4d</b> and <b>4f</b> to mediate apoptosis and arrest cell cycle growth at G1 phase. Furthermore, RT-PCR and Western blot results suggested that both <b>4d</b> and <b>4f</b> activates apoptotic cell death pathway in MCF-7 cells. Molecular docking assessments indicated that compounds <b>4d</b> and <b>4f</b> fit perfectly into Bcl2's active site. Based on the biological properties, we conclude that both compounds <b>4d</b> and <b>4f</b> could be used as a new type of anticancer agent, which provides a scientific basis for further research into the treatment of cancer."]}, "AuthorList": [{"Identifier": ["0000-0002-1034-7441"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Medicinal, Aromatic and Poisonous Plants Research Center, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia."}], "LastName": "Alqahtani", "ForeName": "Ali S", "Initials": "AS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Drug Radiation Research, National Center for Radiation Research and Technology (NCRRT), Egyptian Atomic Energy Authority (EAEA), Nasr City, Cairo 11371, Egypt."}], "LastName": "Ghorab", "ForeName": "Mostafa M", "Initials": "MM"}, {"Identifier": ["0000-0002-6496-7822"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal, Aromatic and Poisonous Plants Research Center, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia."}], "LastName": "Nasr", "ForeName": "Fahd A", "Initials": "FA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Medicinal, Aromatic and Poisonous Plants Research Center, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia."}], "LastName": "Ahmed", "ForeName": "Mohammad Z", "Initials": "MZ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal, Aromatic and Poisonous Plants Research Center, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia."}], "LastName": "Al-Mishari", "ForeName": "Abdullah A", "Initials": "AA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia."}], "LastName": "Attia", "ForeName": "Sabry M", "Initials": "SM"}], "GrantList": [{"GrantID": "13-MED 997-02", "Agency": "King Saud University", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Quinazolines"}, {"RegistryNumber": "0", "NameOfSubstance": "Sulfonamides"}], "MeshHeadingList": [{"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": [], "DescriptorName": "HEK293 Cells"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "In Vitro Techniques"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Quinazolines"}, {"QualifierName": ["chemistry"], "DescriptorName": "Sulfonamides"}], "CoiStatement": "The authors declare that they have no competing interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Ghorab M.M., Ragab F.A., Heiba H.I., Bayomi A.A. Novel quinazoline derivatives bearing a sulfapyridine moiety as anticancer and radiosensitizing agents. J. Heterocycl. Chem. 2014;51:E255\u2013E262. doi: 10.1002/jhet.1830.", "ArticleIdList": ["10.1002/jhet.1830"]}, {"Citation": "Yong J., Lu C., Wu X. Synthesis and Biological Evaluation of Quinazoline Derivatives as Potential Anticancer Agents (II) Anticancer Agents Med. Chem. 2015;15:1326\u20131332. doi: 10.2174/1871520615666150526115904.", "ArticleIdList": ["10.2174/1871520615666150526115904", "26008189"]}, {"Citation": "Poudapally S., Battu S., Velatooru L.R., Bethu M.S., Janapala V.R., Sharma S., Sen S., Pottabathini N., Iska V.B.R., Katangoor V. Synthesis and biological evaluation of novel quinazoline-sulfonamides as anti-cancer agents. Bioorg. Med. Chem. Lett. 2017;27:1923\u20131928. doi: 10.1016/j.bmcl.2017.03.042.", "ArticleIdList": ["10.1016/j.bmcl.2017.03.042", "28351589"]}, {"Citation": "Alagarsamy V., Chitra K., Saravanan G., Solomon V.R., Sulthana M.T., Narendhar B. An overview of quinazolines: Pharmacological significance and recent developments. Eur. J. Med. Chem. 2018;151:628\u2013685. doi: 10.1016/j.ejmech.2018.03.076.", "ArticleIdList": ["10.1016/j.ejmech.2018.03.076", "29656203"]}, {"Citation": "Gridelli C., De Marinis F., Di Maio M., Cortinovis D., Cappuzzo F., Mok T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues. Lung Cancer. 2011;72:3\u20138. doi: 10.1016/j.lungcan.2010.12.009.", "ArticleIdList": ["10.1016/j.lungcan.2010.12.009", "21216488"]}, {"Citation": "Bronte G., Rolfo C., Giovannetti E., Cicero G., Pauwels P., Passiglia F., Castiglia M., Rizzo S., Vullo F.L., Fiorentino E., et al. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Crit. Rev. Oncol. Hematol. 2014;89:300\u2013313. doi: 10.1016/j.critrevonc.2013.08.003.", "ArticleIdList": ["10.1016/j.critrevonc.2013.08.003", "24041630"]}, {"Citation": "Luo Y.-H., Lee Y.-C., Whang-Peng J., Chen Y.-M. Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer. J. Cancer Res. Pract. 2015;2:179\u2013194. doi: 10.6323/JCRP.2015.2.3.01.", "ArticleIdList": ["10.6323/JCRP.2015.2.3.01"]}, {"Citation": "Ismail R.S.M., Ismail N.S.M., Abuserii S., Abou El Ella D.A. Recent advances in 4-aminoquinazoline based scaffold derivatives targeting EGFR kinases as anticancer agents. Future J. Pharm. Sci. 2016;2:9\u201319. doi: 10.1016/j.fjps.2016.02.001.", "ArticleIdList": ["10.1016/j.fjps.2016.02.001"]}, {"Citation": "Bhatia P., Sharma V., Alam O., Manaithiya A., Alam P., Kahksha, Alam M.T., Imran M. Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015\u20132019) Eur. J. Med. Chem. 2020;204:112640. doi: 10.1016/j.ejmech.2020.112640.", "ArticleIdList": ["10.1016/j.ejmech.2020.112640", "32739648"]}, {"Citation": "Bansal R., Malhotra A. Therapeutic progression of quinazolines as targeted chemotherapeutic agents. Eur. J. Med. Chem. 2021;211:113016. doi: 10.1016/j.ejmech.2020.113016.", "ArticleIdList": ["10.1016/j.ejmech.2020.113016", "33243532"]}, {"Citation": "Supuran C.T., Casini A., Mastrolorenzo A., Scozzafava A. COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents. Mini Rev. Med. Chem. 2004;4:625\u2013632. doi: 10.2174/1389557043403792.", "ArticleIdList": ["10.2174/1389557043403792", "15279596"]}, {"Citation": "Solomon V.R., Hu C., Lee H. Hybrid pharmacophore design and synthesis of isatin-benzothiazole analogs for their anti-breast cancer activity. Bioorg. Med. Chem. 2009;17:7585\u20137592. doi: 10.1016/j.bmc.2009.08.068.", "ArticleIdList": ["10.1016/j.bmc.2009.08.068", "19804979"]}, {"Citation": "Ghorab M.M., Alsaid M.S., Al-Dosari M.S., El-Gazzar M.G., Parvez M.K. Design, Synthesis and Anticancer Evaluation of Novel Quinazoline-Sulfonamide Hybrids. Molecules. 2016;21:189. doi: 10.3390/molecules21020189.", "ArticleIdList": ["10.3390/molecules21020189", "PMC6274562", "26861266"]}, {"Citation": "Alkahtani H.M., Abdalla A.N., Obaidullah A.J., Alanazi M.M., Almehizia A.A., Alanazi M.G., Ahmed A.Y., Alwassil O.I., Darwish H.W., Abdel-Aziz A.A., et al. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2. Bioorg. Chem. 2020;95:103461. doi: 10.1016/j.bioorg.2019.103461.", "ArticleIdList": ["10.1016/j.bioorg.2019.103461", "31838290"]}, {"Citation": "Elmore S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007;35:495\u2013516. doi: 10.1080/01926230701320337.", "ArticleIdList": ["10.1080/01926230701320337", "PMC2117903", "17562483"]}, {"Citation": "Mehndiratta S., Sapra S., Singh G., Singh M., Nepali K. Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature. Recent Pat. Anticancer Drug Discov. 2016;11:2\u201366. doi: 10.2174/1574892811666151218151506.", "ArticleIdList": ["10.2174/1574892811666151218151506", "26681186"]}, {"Citation": "Nahta R., Yuan L.X., Du Y., Esteva F.J. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling. Mol. Cancer. 2007;6:667\u2013674. doi: 10.1158/1535-7163.MCT-06-0423.", "ArticleIdList": ["10.1158/1535-7163.MCT-06-0423", "17308062"]}, {"Citation": "Ling Y.H., Lin R., Perez-Soler R. Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. Mol. Pharm. 2008;74:793\u2013806. doi: 10.1124/mol.107.044396.", "ArticleIdList": ["10.1124/mol.107.044396", "18524889"]}, {"Citation": "Gong H.H., Addla D., Lv J.S., Zhou C.H. Heterocyclic Naphthalimides as New Skeleton Structure of Compounds with Increasingly Expanding Relational Medicinal Applications. Curr. Top. Med. Chem. 2016;16:3303\u20133364. doi: 10.2174/1568026616666160506145943.", "ArticleIdList": ["10.2174/1568026616666160506145943", "27150364"]}, {"Citation": "Ghorab M.M., Alsaid M.S., Soliman A.M., Ragab F.A. VEGFR-2 inhibitors and apoptosis inducers: Synthesis and molecular design of new benzo[g]quinazolin bearing benzenesulfonamide moiety. J. Enzym. Inhib. Med. Chem. 2017;32:893\u2013907. doi: 10.1080/14756366.2017.1334650.", "ArticleIdList": ["10.1080/14756366.2017.1334650", "PMC6445170", "28661197"]}, {"Citation": "Ghorab M.M., Alsaid M.S., Soliman A.M., Al-Mishari A.A. Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors. J. Enzym. Inhib. Med. Chem. 2018;33:67\u201373. doi: 10.1080/14756366.2017.1389922.", "ArticleIdList": ["10.1080/14756366.2017.1389922", "PMC6010119", "29098904"]}, {"Citation": "Alqahtani A.S., Ghorab M.M., Nasr F.A., Ahmed M.Z., Al-Mishari A.A., Attia S.M. Novel sulfonamide-bearing methoxyquinazolinone derivatives as anticancer and apoptosis inducers: Synthesis, biological evaluation and in silico studies. J. Enzym. Inhib. Med. Chem. 2022;37:86\u201399. doi: 10.1080/14756366.2021.1983807.", "ArticleIdList": ["10.1080/14756366.2021.1983807", "PMC8667930", "34894963"]}, {"Citation": "Alimbetov D., Askarova S., Umbayev B., Davis T., Kipling D. Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells. Int. J. Mol. Sci. 2018;19:1690. doi: 10.3390/ijms19061690.", "ArticleIdList": ["10.3390/ijms19061690", "PMC6032165", "29882812"]}, {"Citation": "Sun Y., Liu Y., Ma X., Hu H. The Influence of Cell Cycle Regulation on Chemotherapy. Int. J. Mol. Sci. 2021;22:6923. doi: 10.3390/ijms22136923.", "ArticleIdList": ["10.3390/ijms22136923", "PMC8267727", "34203270"]}, {"Citation": "Zheng L., Wang X., Luo W., Zhan Y., Zhang Y. Brucine, an effective natural compound derived from nux-vomica, induces G1 phase arrest and apoptosis in LoVo cells. Food Chem. Toxicol. 2013;58:332\u2013339. doi: 10.1016/j.fct.2013.05.011.", "ArticleIdList": ["10.1016/j.fct.2013.05.011", "23688861"]}, {"Citation": "Pfeffer C.M., Singh A.T.K. Apoptosis: A Target for Anticancer Therapy. Int. J. Mol. Sci. 2018;19:448. doi: 10.3390/ijms19020448.", "ArticleIdList": ["10.3390/ijms19020448", "PMC5855670", "29393886"]}, {"Citation": "Wlodkowic D., Skommer J., Darzynkiewicz Z. Flow cytometry-based apoptosis detection. Methods Mol. Biol. 2009;559:19\u201332. doi: 10.1007/978-1-60327-017-5_2.", "ArticleIdList": ["10.1007/978-1-60327-017-5_2", "PMC3863590", "19609746"]}, {"Citation": "Yip K.W., Reed J.C. Bcl-2 family proteins and cancer. Oncogene. 2008;27:6398\u20136406. doi: 10.1038/onc.2008.307.", "ArticleIdList": ["10.1038/onc.2008.307", "18955968"]}, {"Citation": "Warren C.F.A., Wong-Brown M.W., Bowden N.A. BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis. 2019;10:177. doi: 10.1038/s41419-019-1407-6.", "ArticleIdList": ["10.1038/s41419-019-1407-6", "PMC6384907", "30792387"]}, {"Citation": "Kale J., Osterlund E.J., Andrews D.W. BCL-2 family proteins: Changing partners in the dance towards death. Cell Death Differ. 2018;25:65\u201380. doi: 10.1038/cdd.2017.186.", "ArticleIdList": ["10.1038/cdd.2017.186", "PMC5729540", "29149100"]}, {"Citation": "Lamkanfi M., Kanneganti T.-D. Caspase-7: A protease involved in apoptosis and inflammation. Int J. Biochem. Cell Biol. 2010;42:21\u201324. doi: 10.1016/j.biocel.2009.09.013.", "ArticleIdList": ["10.1016/j.biocel.2009.09.013", "PMC2787741", "19782763"]}, {"Citation": "Brentnall M., Rodriguez-Menocal L., De Guevara R.L., Cepero E., Boise L.H. Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol. 2013;14:32. doi: 10.1186/1471-2121-14-32.", "ArticleIdList": ["10.1186/1471-2121-14-32", "PMC3710246", "23834359"]}, {"Citation": "Zahedifard M., Faraj F.L., Paydar M., Looi C.Y., Hasandarvish P., Hajrezaie M., Kamalidehghan B., Majid N.A., Khalifa S.A., Ali H.M., et al. Synthesis of Apoptotic New Quinazolinone-Based Compound and Identification of its Underlying Mitochondrial Signalling Pathway in Breast Cancer Cells. Curr. Pharm. Des. 2015;21:3417\u20133426. doi: 10.2174/1381612821666150326104952.", "ArticleIdList": ["10.2174/1381612821666150326104952", "25808938"]}, {"Citation": "Nowar R.M., EE A.O., Abou-Seri S.M., El Moghazy S.M., Abou El Ella D.A. Design, synthesis and biological evaluation of some novel quinazolinone derivatives as potent apoptotic inducers. Future Med. Chem. 2018;10:1191\u20131205. doi: 10.4155/fmc-2017-0284.", "ArticleIdList": ["10.4155/fmc-2017-0284", "29749767"]}, {"Citation": "ElZahabi H.S.A., Nafie M.S., Osman D., Elghazawy N.H., Soliman D.H., El-Helby A.A.H., Arafa R.K. Design, synthesis and evaluation of new quinazolin-4-one derivatives as apoptotic enhancers and autophagy inhibitors with potent antitumor activity. Eur. J. Med. Chem. 2021;222:113609. doi: 10.1016/j.ejmech.2021.113609.", "ArticleIdList": ["10.1016/j.ejmech.2021.113609", "34119830"]}, {"Citation": "Ariyama H., Qin B., Baba E., Tanaka R., Mitsugi K., Harada M., Nakano S. Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. J. Cell Biochem. 2006;97:724\u2013734. doi: 10.1002/jcb.20678.", "ArticleIdList": ["10.1002/jcb.20678", "16229013"]}, {"Citation": "Liu L., Zhong L., Zhao Y., Chen M., Yao S., Li L., Xiao C., Shan Z., Gan L., Xu T., et al. Effects of lapatinib on cell proliferation and apoptosis in NB4 cells. Oncol. Lett. 2018;15:235\u2013242. doi: 10.3892/ol.2017.7342.", "ArticleIdList": ["10.3892/ol.2017.7342", "PMC5768102", "29387217"]}, {"Citation": "Krishna S., Kumar S.B., Murthy T.P.K., Murahari M. Structure-based design approach of potential BCL-2 inhibitors for cancer chemotherapy. Comput. Biol. Med. 2021;134:104455. doi: 10.1016/j.compbiomed.2021.104455.", "ArticleIdList": ["10.1016/j.compbiomed.2021.104455", "33962088"]}, {"Citation": "AlAjmi M.F., Rehman M.T., Hussain A., Rather G.M. Pharmacoinformatics approach for the identification of Polo-like kinase-1 inhibitors from natural sources as anti-cancer agents. Int. J. Biol. Macromol. 2018;116:173\u2013181. doi: 10.1016/j.ijbiomac.2018.05.023.", "ArticleIdList": ["10.1016/j.ijbiomac.2018.05.023", "29738867"]}, {"Citation": "Nasr F.A., Shahat A.A., Alqahtani A.S., Ahmed M.Z., Qamar W., Al-Mishari A.A., Almoqbil A.N. Centaurea bruguierana inhibits cell proliferation, causes cell cycle arrest, and induces apoptosis in human MCF-7 breast carcinoma cells. Mol. Biol. Rep. 2020;47:6043\u20136051. doi: 10.1007/s11033-020-05679-x.", "ArticleIdList": ["10.1007/s11033-020-05679-x", "32700127"]}, {"Citation": "Alqahtani A.S., Nasr F.A., Noman O.M., Farooq M., Alhawassi T., Qamar W., El-Gamal A. Cytotoxic Evaluation and Anti-Angiogenic Effects of Two Furano-Sesquiterpenoids from Commiphora myrrh Resin. Molecules. 2020;25:1318. doi: 10.3390/molecules25061318.", "ArticleIdList": ["10.3390/molecules25061318", "PMC7144466", "32183153"]}, {"Citation": "Rio D.C., Ares M., Hannon G.J., Nilsen T.W. Purification of RNA using TRIzol (TRI reagent) Cold Spring Harb. Protoc. 2010;2010:pdb.prot5439. doi: 10.1101/pdb.prot5439.", "ArticleIdList": ["10.1101/pdb.prot5439", "20516177"]}, {"Citation": "Al-Shabib N.A., Khan J.M., Malik A., Alsenaidy M.A., Rehman M.T., AlAjmi M.F., Alsenaidy A.M., Husain F.M., Khan R.H. Molecular insight into binding behavior of polyphenol (rutin) with beta lactoglobulin: Spectroscopic, molecular docking and MD simulation studies. J. Mol. Liq. 2018;269:511\u2013520. doi: 10.1016/j.molliq.2018.07.122.", "ArticleIdList": ["10.1016/j.molliq.2018.07.122"]}, {"Citation": "Porter J., Payne A., De Candole B., Ford D., Hutchinson B., Trevitt G., Turner J., Edwards C., Watkins C., Whitcombe I., et al. Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors. Bioorg. Med. Chem. Lett. 2009;19:230\u2013233. doi: 10.1016/j.bmcl.2008.10.113.", "ArticleIdList": ["10.1016/j.bmcl.2008.10.113", "19027294"]}, {"Citation": "Rehman M.T., Shamsi H., Khan A.U. Insight into the binding mechanism of imipenem to human serum albumin by spectroscopic and computational approaches. Mol. Pharm. 2014;11:1785\u20131797. doi: 10.1021/mp500116c.", "ArticleIdList": ["10.1021/mp500116c", "24745377"]}, {"Citation": "Rabbani N., Tabrez S., Islam B.U., Rehman M.T., Alsenaidy A.M., AlAjmi M.F., Khan R.A., Alsenaidy M.A., Khan M.S. Characterization of colchicine binding with normal and glycated albumin: In vitro and molecular docking analysis. J. Biomol. Struct. Dyn. 2018;36:3453\u20133462. doi: 10.1080/07391102.2017.1389661.", "ArticleIdList": ["10.1080/07391102.2017.1389661", "28990867"]}, {"Citation": "Rehman M.T., Ahmed S., Khan A.U. Interaction of meropenem with \u2018N\u2019 and \u2018B\u2019 isoforms of human serum albumin: A spectroscopic and molecular docking study. J. Biomol. Struct. Dyn. 2016;34:1849\u20131864. doi: 10.1080/07391102.2015.1094411.", "ArticleIdList": ["10.1080/07391102.2015.1094411", "26372227"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "12", "Day": "16"}, {"Year": "2022", "Month": "1", "Day": "26"}, {"Year": "2022", "Month": "1", "Day": "27"}, {"Year": "2022", "Month": "2", "Day": "15", "Hour": "1", "Minute": "20"}, {"Year": "2022", "Month": "2", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "2", "Day": "19", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "2", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["35164248", "PMC8838787", "10.3390/molecules27030981", "molecules27030981"]}}], "PubmedBookArticle": []}